Empagliflozin Not Tied to Risk for New Nonproliferative Diabetic Retinopathy

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 18, 2024.

By Lori Solomon HealthDay Reporter

TUESDAY, Dec. 17, 2024 -- Empagliflozin initiation is not associated with incident nonproliferative diabetic retinopathy (NPDR) compared with initiation of a dipeptidyl peptidase 4 inhibitor (DPP4i), according to a study published online Dec. 5 in JAMA Ophthalmology.

Helen Tesfaye, Pharm.D., from Brigham and Women’s Hospital in Boston, and colleagues compared the risk for incident NPDR and DR progression in patients with type 2 diabetes (T2D) initiating empagliflozin versus a DPP4i. The analysis included 34,239 pairs of propensity score-matched adults in the incident NPDR cohort and 7,831 pairs in the DR progression cohort.

The researchers found that during a mean follow-up period of eight months receiving treatment, the risk for incident NPDR did not differ across groups (hazard ratio [HR], 1.04; 95 percent confidence interval [CI], 0.94 to 1.15; rate difference [RD], 1.30; 95 percent CI, −1.83 to 4.44). The risk for DR progression was lower among individuals who initiated empagliflozin versus those who began DPP4i therapy (HR, 0.78; 95 percent CI, 0.63 to 0.96; RD, −9.44; 95 percent CI, −16.90 to −1.98). Across multiple subgroups and sensitivity analyses, results were similar.

"Although residual confounding cannot be entirely ruled out due to the observational nature of our study, these findings may be helpful when weighing the risks and benefits of various glucose-lowering agents in adults with T2D," the authors write.

Several authors disclosed ties to pharmaceutical companies, including Boehringer Ingelheim and Eli Lilly, which manufacture empagliflozin; Boehringer Ingelheim funded the study.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-12-19 00:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords